High expression of CPT1 has been reported in breast cancer [26], lung cancer [27], gastric cancer [28], prostate cancer [29], ovarian cancer [30], nasopharyngeal cancer [31] and chronic lymphoblastic leukemia [32]. Here, CPT2 is linked to prostate carcinoma.